101 related articles for article (PubMed ID: 8377507)
1. Monoclonal antibody KP16D3 as a prognostic marker in stage I lung adenocarcinoma.
Suehiro T; Ishida T; Sugio K; Sugimachi K; Sueishi K
J Surg Oncol; 1993 Sep; 54(1):51-6. PubMed ID: 8377507
[TBL] [Abstract][Full Text] [Related]
2. Immunohistochemical study of lung adenocarcinoma using monoclonal antibody for 60-kilodalton antigen in type II pneumocytes and nonciliated bronchiolar epithelial cells. Comparison with two antisurfactant apoprotein antibodies.
Suehiro T; Maeda K; Sueishi K
Am J Clin Pathol; 1989 Aug; 92(2):150-8. PubMed ID: 2547307
[TBL] [Abstract][Full Text] [Related]
3. Expression of Thomsen-Friedenreich antigen as a marker of poor prognosis in pulmonary adenocarcinoma.
Takanami I
Oncol Rep; 1999; 6(2):341-4. PubMed ID: 10023001
[TBL] [Abstract][Full Text] [Related]
4. Id-1, Id-2, and Id-3 co-expression correlates with prognosis in stage I and II lung adenocarcinoma patients treated with surgery and adjuvant chemotherapy.
Antonângelo L; Tuma T; Fabro A; Acencio M; Terra R; Parra E; Vargas F; Takagaki T; Capelozzi V
Exp Biol Med (Maywood); 2016 Jun; 241(11):1159-68. PubMed ID: 26869608
[TBL] [Abstract][Full Text] [Related]
5. Heat shock protein 90-β over-expression is associated with poor survival in stage I lung adenocarcinoma patients.
Wu Y; Huang B; Liu Q; Liu Y
Int J Clin Exp Pathol; 2015; 8(7):8252-9. PubMed ID: 26339394
[TBL] [Abstract][Full Text] [Related]
6. Immunoreactivity of monoclonal antibody BW835 represents a marker of progression and prognosis in early gastric cancer.
Baldus SE; Zirbes TK; Glossmann J; Fromm S; Hanisch FG; Mönig SP; Schröder W; Schneider PM; Flucke U; Karsten U; Thiele J; Hölscher AH; Dienes HP
Oncology; 2001; 61(2):147-55. PubMed ID: 11528254
[TBL] [Abstract][Full Text] [Related]
7. Value of the MOC-31 monoclonal antibody in differentiating epithelial pleural mesothelioma from lung adenocarcinoma.
Ordóñez NG
Hum Pathol; 1998 Feb; 29(2):166-9. PubMed ID: 9490276
[TBL] [Abstract][Full Text] [Related]
8. Immunohistochemical detection of eosinophilic infiltration in pulmonary adenocarcinoma.
Takanami I; Takeuchi K; Gika M
Anticancer Res; 2002; 22(4):2391-6. PubMed ID: 12174932
[TBL] [Abstract][Full Text] [Related]
9. ANCCA protein expression is a novel independent poor prognostic marker in surgically resected lung adenocarcinoma.
Zhang Y; Sun Y; Li Y; Fang Z; Wang R; Pan Y; Hu H; Luo X; Ye T; Li H; Wang L; Chen H; Ji H
Ann Surg Oncol; 2013 Dec; 20 Suppl 3():S577-82. PubMed ID: 23775406
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of grading systems in stage I lung adenocarcinomas: a retrospective cohort study.
Zombori T; Furák J; Nyári T; Cserni G; Tiszlavicz L
J Clin Pathol; 2018 Feb; 71(2):135-140. PubMed ID: 28747392
[TBL] [Abstract][Full Text] [Related]
11. Ly6/uPAR-related protein C4.4A as a marker of solid growth pattern and poor prognosis in lung adenocarcinoma.
Jacobsen B; Muley T; Meister M; Dienemann H; Christensen IJ; Santoni-Rugiu E; Lærum OD; Ploug M
J Thorac Oncol; 2013 Feb; 8(2):152-60. PubMed ID: 23287851
[TBL] [Abstract][Full Text] [Related]
12. Peroxiredoxin 4 as an independent prognostic marker for survival in patients with early-stage lung squamous cell carcinoma.
Hwang JA; Song JS; Yu DY; Kim HR; Park HJ; Park YS; Kim WS; Choi CM
Int J Clin Exp Pathol; 2015; 8(6):6627-35. PubMed ID: 26261544
[TBL] [Abstract][Full Text] [Related]
13. Non-terminal respiratory unit type lung adenocarcinoma has three distinct subtypes and is associated with poor prognosis.
Sumiyoshi S; Yoshizawa A; Sonobe M; Kobayashi M; Sato M; Fujimoto M; Tsuruyama T; Date H; Haga H
Lung Cancer; 2014 Jun; 84(3):281-8. PubMed ID: 24725383
[TBL] [Abstract][Full Text] [Related]
14. Expression of RACK1 is a novel biomarker in pulmonary adenocarcinomas.
Nagashio R; Sato Y; Matsumoto T; Kageyama T; Satoh Y; Shinichiro R; Masuda N; Goshima N; Jiang SX; Okayasu I
Lung Cancer; 2010 Jul; 69(1):54-9. PubMed ID: 19892429
[TBL] [Abstract][Full Text] [Related]
15. Chaperone protein L-isoaspartate (D-aspartyl) O-methyltransferase as a novel predictor of poor prognosis in lung adenocarcinoma.
Saito H; Yamashita M; Ogasawara M; Yamada N; Niisato M; Tomoyasu M; Deguchi H; Tanita T; Ishida K; Sugai T; Yamauchi K
Hum Pathol; 2016 Apr; 50():1-10. PubMed ID: 26997432
[TBL] [Abstract][Full Text] [Related]
16. Useful prognostic panel markers to express the biological tumor status in resected lung adenocarcinomas.
Carvalho PE; Antonãngelo L; Bernardi FD; Leão LE; Rodrigues OR; Capelozzi VL
Jpn J Clin Oncol; 2000 Nov; 30(11):478-86. PubMed ID: 11155917
[TBL] [Abstract][Full Text] [Related]
17. Clinicopathological and prognostic significance of programmed cell death ligand-1 expression in lung adenocarcinoma and its relationship with p53 status.
Cha YJ; Kim HR; Lee CY; Cho BC; Shim HS
Lung Cancer; 2016 Jul; 97():73-80. PubMed ID: 27237031
[TBL] [Abstract][Full Text] [Related]
18. Basigin expression as a prognostic indicator in stage I pulmonary adenocarcinoma.
Matsumoto T; Nagashio R; Ryuge S; Igawa S; Kobayashi M; Fukuda E; Goshima N; Ichinoe M; Jiang SX; Satoh Y; Masuda N; Murakumo Y; Saegusa M; Sato Y
Pathol Int; 2018 Apr; 68(4):232-240. PubMed ID: 29431238
[TBL] [Abstract][Full Text] [Related]
19. ROR1 is a novel prognostic biomarker in patients with lung adenocarcinoma.
Zheng YZ; Ma R; Zhou JK; Guo CL; Wang YS; Li ZG; Liu LX; Peng Y
Sci Rep; 2016 Nov; 6():36447. PubMed ID: 27830754
[TBL] [Abstract][Full Text] [Related]
20. Psf3 is a prognostic biomarker in lung adenocarcinoma: a larger trial using tissue microarrays of 864 consecutive resections.
Tauchi S; Sakai Y; Fujimoto S; Ogawa H; Tane S; Hokka D; Tanaka Y; Nishio W; Yoshimura M; Yanagita E; Itoh T; Hayashi Y; Maniwa Y
Eur J Cardiothorac Surg; 2016 Oct; 50(4):758-764. PubMed ID: 27005977
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
